RA Capital Management Boosts Evommune Stake to 9.7% via $1M Private Placement Purchase
EVMN has more than doubled off its 52-week low of $13.885.
Summary
RA Capital Management, a significant institutional investor, increased its stake in Evommune, Inc. by purchasing approximately $1 million in common stock through a recent private placement, bringing its total beneficial ownership to 9.7%.
Key Events · Ownership and Investor Activity · EVMN
-
RA Capital's Increased Stake
RA Capital Management, L.P. and its affiliates now beneficially own 3,494,638 shares, representing 9.7% of Evommune's common stock.
-
Participation in Private Placement
RA Capital Healthcare Fund, L.P. purchased 35,868 shares for approximately $1 million in the February 2026 Private Placement.
-
Pricing and Context
The shares were acquired at $27.88 per share, part of the larger $125 million private placement announced on February 13, 2026, which followed positive Phase 2a trial results.
Analysis · EVMN · Life Sciences
This Schedule 13D/A reveals that RA Capital Management, a prominent institutional investor, has increased its beneficial ownership in Evommune, Inc. to 9.7% by participating in the recently announced private placement. The purchase of approximately $1 million in common stock by RA Capital Healthcare Fund, L.P. at $27.88 per share signals continued confidence from a major investor, especially following the highly positive Phase 2a trial results for EVO301 reported on February 10, 2026, and the successful $125 million capital raise announced on February 13, 2026. This participation by a sophisticated investor in a dilutive offering, particularly after significant clinical data, can be interpreted as a positive endorsement of the company's prospects and its ability to fund future development. The filing also notes a Registration Rights Agreement, which is standard for such private placements, facilitating future liquidity for the investors.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $31.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $983.6M. The 52-week trading range was $13.89 to $33.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.